Showing 1321-1330 of 3001 results for "".
- Ponesimod Superior to Teriflunomide for Relapsing Multiple Sclerosis in Phase 3 Trialhttps://practicalneurology.com/news/ponesimod-superior-to-teriflunomide-for-relapsing-multiple-sclerosis-in-phase-3-trial/2469015/In the phase 3 OPTIMUM study (NCT02425644), adults with relapsing multiple sclerosis (MS) treated with ponesimod (Janssen Pharmaceuticals, Titusville, NJ) had a 30.5% reduction in annualized relapse rate (ARR) compared with those treat
- Determining Optimal Treatment Strategies for Multiple Sclerosishttps://practicalneurology.com/news/determining-optimal-treatment-strategies-for-multiple-sclerosis/2468988/A review published in Lancet Neurology makes the case that well-powered randomized clinical trials to compare treatment strategies for multiple sclerosis (MS) are necessary and possible. Authore
- Patient's Risk Tolerance for Disease Modifying Treatments for Multiple Sclerosishttps://practicalneurology.com/news/patients-risk-tolerance-for-disease-modifying-treatments-for-multiple/2468799/In a study published in Neurology, researchers at the Cleveland Clinic evaluated patients’ tolerance for potential risks of multiple sclerosis (MS) medications. Studies show that 40% or more of
- Multiple Sclerosis Prevalence May Be Twice As High as Previously Thoughthttps://practicalneurology.com/news/multiple-sclerosis-prevalence-may-be-twice-as-high-as-previously-thought/2468830/A study published in the journal Neurology suggests prevalence of multiple sclerosis (MS) in the US is 913,925—more than twice the previous estimate of 400,000 people in
- 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research Presented to Lars Lannfelt, MD, PhDhttps://practicalneurology.com/news/2024-lifetime-achievement-award-in-alzheimers-disease-therapeutic-research-presented-to-lars-lannfelt-md-phd/2470618/Lars Lannfelt, MD, PhD has been recognized as the recipient of the 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference. Dr. Lannfelt was selected based on his pioneering work in Alzheim
- UCSF Professor Bruce Ovbiagele, MD Recognized with Scientific Breakthrough Award at AAN 2024https://practicalneurology.com/news/ucsf-professor-bruce-ovbiagele-md-recognized-with-scientific-breakthrough-award-at-aan-2024/2470442/This year, the American Brain Foundation (ABF) awarded Bruce Ovbiagele, MD, MAS, FAAN the annual Scientific Breakthrough Award. Dr Ovbiagele, a Professor of Neurology at University of California (UC) San Francisco and Associate Dean of the San Francisco Veterans Affairs (VA) Healthcare Syste
- 2024 McDonald Criteria Revisions Published in The Lancet Neurologyhttps://practicalneurology.com/news/2024-mcdonald-criteria-revisions-published-in-the-lancet-neurology/2483516/The 2024 revisions to the McDonald criteria for the diagnosis of multiple sclerosis (MS) have been published in The Lancet Neurology in September 2025, marking the first major update since 2017. The criteria were updated to reflect significant changes in the field, including an evolving
- Higher Relapse and Adverse Event Rates Reported with Generic Fingolimod vs Gilenyahttps://practicalneurology.com/news/higher-relapse-and-adverse-event-rates-reported-with-generic-fingolimod-vs-gilenya/2474993/A retrospective study presented at the 2025 Annual Meeting of The Consortium of Multiple Sclerosis Centers examined clinical and radiologic outcomes in patients with multiple sclerosis (MS) who transitioned from branded Gilenya (Novartis; East Hanover, NJ) treatment to generic fingolimod. The ana
- Long-Term Data Reveal Ocrevus Comparable to Tysabri Tx in Effectiveness, Safety Outcomeshttps://practicalneurology.com/news/long-term-data-reveals-ocrevus-comparable-to-tysabri-tx-in-effectiveness-safety-outcomes/2470583/Treatment with Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) for people with multiple sclerosis (MS) showed comparable effectiveness, safety, and treatment persistence to treatment with Tysabri (natalizumab; Biogen, Cambridge, MA) over a 5-year observation period. The results of a lon
- Fumarates and S1Ps Have Comparable Effectiveness in Black Patients with Relapsing Multiple Sclerosishttps://practicalneurology.com/news/fumarates-and-s1ps-have-comparable-effectiveness-in-black-patients-with-relapsing-multiple-sclerosis-1/2470489/Fumarates and sphingosine-1-phosphate receptor modulators (S1Ps), 2 types of disease-modifying therapy (DMT), were shown to have comparable effectiveness when used to treat Black patients with relapsing multiple sclerosis (MS). The findings, which were presented at the 24th Annual Meeting of the